doctor NO
NO nel DNA
vedo che ami il rischio
un'annuncio potrebbe arrivare ad ogni momento sai che bello aver aspettato anni e poi adesso che le hai vendute BBBBBBOOOOOOOOOOOOOOOOOMMMMMMMM
NicOx : Garufi ... e la Rivoluzione Pharma
- Creatore Discussione Yesod
- Data di Inizio
- Stato
un'annuncio potrebbe arrivare ad ogni momento sai che bello aver aspettato anni e poi adesso che le hai vendute BBBBBBOOOOOOOOOOOOOOOOOMMMMMMMM
magolibero
..se la sà gira..
nuovo studio su Naprox ??
fase I
update del 27/05
http://www.clinicaltrial.gov/ct2/show/NCT00909519
..
Health Authority:Switzerland: Swissmedic
..
fase I
update del 27/05
http://www.clinicaltrial.gov/ct2/show/NCT00909519
..
Health Authority:Switzerland: Swissmedic
..
viralic
Forumer storico
Secondo me...........ma posso umanamente errare..........questa è strategia pura..........il partner non c'è ma far credere ad altri big che gli accordi possono essere siglati da un momento all'altro serve per far muovere le acque stagnanti in cui siamo..............
Infatti ennesima falsa partenza sulle voci e poi tutto ritorna al punto iniziale.............e guarda caso in un giorno in cui le borse perdono....come dire........quando potrebbe abbassarsi il prezzo teniamolo alto .............strano che quando le borse salgono il titoo di solito scende...come dire........oggi non è necessario sostenerlo.............bah.........come dice il grande Netzach...........qui qualcosa non quadra !!
tradermen
Forumer storico
io dico che solo dopo l' AG qualcosa salterà fuori..x il semplice motivo, parer mio, che un annuncio ora potrebbe far salire di molto il prezzo e questo nn rientrebbe nei programmi di un ak riservato ..
viralic
Forumer storico
Possibile.............come è anche possibile che il partner salterà fuori solo dopo l'accettazione ( non l'approvazione che arriva solo dopo 6/12 mesi) da parte della FDA del Naproxcinod...quindi dopo circa 60 giorni dalla presentazione..........In questo modo un manager non rischia di essere segato in caso di fallimento della molecola da parte della azienda big pharma............questi oggi sono i nuovi parametri con cui dobbiamo confrontarsi...........tutto il resto è pompaggio .......e aria fritta.quella che io personalmente annuso da 2 anni !!
viralic
Forumer storico
Morale: volete il partner ???.............spero veramente e sinceramente di sbagliarmi, ma prima di ottobre/novembre 2009 non se ne parla.............c'è tempo per comprare e c'è tempo per speculare su altro !!!..............come fanno quasi tutti qui dentro d'altronde alla faccia dei cessi, latrine, tavernelli, bovini, suini, cammelli, triceratopi, tirannosauri, e ........beh fate voi !!!
Nicox era il loro unico verbo..............poi però una buona parte della cassa l'hanno messa su altro nel nasdaq.........e stanno facendo ......soldi !!!
Nicox era il loro unico verbo..............poi però una buona parte della cassa l'hanno messa su altro nel nasdaq.........e stanno facendo ......soldi !!!
Ultima modifica:
doctor NO
NO nel DNA
doctor NO
NO nel DNA
messaggio di importanza vitale<<<<<<<<<<<<<<<<<<< attivatevi per votare tutte le risoluzioni fate i passi necessari affinchè tutti i voti siano presenti per l'AG del17 giugno !!!!!!!!!!!!! rompete le palle a quei burocrati che vi mettono mille paletti davanti !!!!!!!!!!!!!
doctor NO
NO nel DNA
update Reuters Auj. à 15:45
* NicOx on track with naproxcinod U.S., EU filing plans
* Naproxcinod likely to be partnered with multiple companies
* Share rises 4.18 percent after interview
(Adds CEO comments, background)
By Caroline Jacobs and Noelle Mennella
PARIS, June 3 (Reuters) - NicOx expects to sign several partnership agreements for its candidate drug naproxcinod, which it still plans to submit for U.S. marketing approval this summer and EU approval this autumn.
"If we find a partner that is as good in Europe as in the United States, we will do a deal with them," Chief Executive Michele Garufi told Reuters on Wednesday.
"I think it will be easier to have several partners. It is likely that we will have two or even three partners, for Europe, the U.S. and Japan," he added.
Garufi said he expected to strike such deals this year or next. He declined to comment on which of the world's many drug firms would be good candidates for NicOx.
But the drug, a possible competitor to Pfizer's blockbuster Celebrex, still needs to be submitted for marketing approval in the United States and Europe.
"We don't need a partner for filing (for marketing approval), we can file on our own in the United States and in Europe," Garufi said. "We will first submit it and the rest follows automatically."
NicOx's plans to become a pharmaceutical company by buying products complementary to its portfolio from other companies partly hinges on its ability to strike a marketing deal in the United States, the world's biggest drug market.
A deal would entail NicOx keeping the rights to market the product to specialists while its partner, with a big sales force, would sell it to general practitioners.
PLENTY OF CASH UNTIL END 2010
At the end of March, NicOx had 84.6 million euros in cash, which Garufi said was enough to run its business until the end of 2010.
NicOx uses its nitric oxide-donating technology to develop drugs against inflammatory and cardio-metabolic diseases and significantly strengthened its patent portfolio when it bought patents from Nitromed .
Garufi declined to say what NicOx's plans were for the new patents or what diseases they could be used for.
"It's a defensive strategy and it is also meant for future projects," Garufi said.
Nitric oxide acts as a messenger molecule in the body but certain diseases are linked to a lack of nitric oxide production. NicOx's technology involves grafting a nitric oxide-donating chemical group onto an existing drug molecule, forming a new chemical entity that can be patented.
It recently began the clinical development of cardiovascular compound NCX 6560, which will be compared with a placebo and Pfizer's cholestorol drug Lipitor, the world's top selling drug. Results are due in the third quarter, Garufi said.
NicOx shares rose 4.18 percent to 9.48 euros on Wednesday, giving the company a stock market value of around 450 million euros. The stock has increased 18.2 percent this year
* NicOx on track with naproxcinod U.S., EU filing plans
* Naproxcinod likely to be partnered with multiple companies
* Share rises 4.18 percent after interview
(Adds CEO comments, background)
By Caroline Jacobs and Noelle Mennella
PARIS, June 3 (Reuters) - NicOx expects to sign several partnership agreements for its candidate drug naproxcinod, which it still plans to submit for U.S. marketing approval this summer and EU approval this autumn.
"If we find a partner that is as good in Europe as in the United States, we will do a deal with them," Chief Executive Michele Garufi told Reuters on Wednesday.
"I think it will be easier to have several partners. It is likely that we will have two or even three partners, for Europe, the U.S. and Japan," he added.
Garufi said he expected to strike such deals this year or next. He declined to comment on which of the world's many drug firms would be good candidates for NicOx.
But the drug, a possible competitor to Pfizer's blockbuster Celebrex, still needs to be submitted for marketing approval in the United States and Europe.
"We don't need a partner for filing (for marketing approval), we can file on our own in the United States and in Europe," Garufi said. "We will first submit it and the rest follows automatically."
NicOx's plans to become a pharmaceutical company by buying products complementary to its portfolio from other companies partly hinges on its ability to strike a marketing deal in the United States, the world's biggest drug market.
A deal would entail NicOx keeping the rights to market the product to specialists while its partner, with a big sales force, would sell it to general practitioners.
PLENTY OF CASH UNTIL END 2010
At the end of March, NicOx had 84.6 million euros in cash, which Garufi said was enough to run its business until the end of 2010.
NicOx uses its nitric oxide-donating technology to develop drugs against inflammatory and cardio-metabolic diseases and significantly strengthened its patent portfolio when it bought patents from Nitromed .
Garufi declined to say what NicOx's plans were for the new patents or what diseases they could be used for.
"It's a defensive strategy and it is also meant for future projects," Garufi said.
Nitric oxide acts as a messenger molecule in the body but certain diseases are linked to a lack of nitric oxide production. NicOx's technology involves grafting a nitric oxide-donating chemical group onto an existing drug molecule, forming a new chemical entity that can be patented.
It recently began the clinical development of cardiovascular compound NCX 6560, which will be compared with a placebo and Pfizer's cholestorol drug Lipitor, the world's top selling drug. Results are due in the third quarter, Garufi said.
NicOx shares rose 4.18 percent to 9.48 euros on Wednesday, giving the company a stock market value of around 450 million euros. The stock has increased 18.2 percent this year
- Stato